[
    {
        "category": "company",
        "datetime": 1743522007,
        "headline": "GILD or AMGN: Which Is the Better Value Stock Right Now?",
        "id": 133655234,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "GILD vs. AMGN: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=4a606a31dbc49f767cf9afc7f05806d74555d9134bd2e4120d87627ed51612d3"
    },
    {
        "category": "company",
        "datetime": 1743521400,
        "headline": "Dow falls nearly 150 points on losses for Johnson & Johnson, Merck shares",
        "id": 133658793,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow falls nearly 150 points on losses for Johnson & Johnson, Merck shares",
        "url": "https://finnhub.io/api/news?id=c9d70736961831c69fccafebef0832d2e0f9e5e864e8e345b889072023cf7e19"
    },
    {
        "category": "company",
        "datetime": 1743509147,
        "headline": "Dogs Of The Dow Chase April's 'Safer' Buy",
        "id": 133646857,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=2feed9044f044f2d4cb8422e3537e5db1ce869843f4c4367a375d4fa0a997d66"
    },
    {
        "category": "company",
        "datetime": 1743507861,
        "headline": "Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1",
        "id": 133645081,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The overseers of the Dow Jones Industrial Average might regret adding Nvidia to the index.  Since it joined the Dow industrials on Nov. 7, Nvidia stock is down nearly 30%.  Nvidia stock is on track for its worst month since September 2022, when it lost nearly 20%, according to Dow Jones Market Data.",
        "url": "https://finnhub.io/api/news?id=97e400b522bf5e518c45d955870c9c3706affed7b7ff749600e31a67ec75a38d"
    },
    {
        "category": "company",
        "datetime": 1743507025,
        "headline": "These biotech names aren't facing 'huge concern' from tariffs",
        "id": 133645380,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime\u00a0here.",
        "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce"
    },
    {
        "category": "company",
        "datetime": 1743458415,
        "headline": "Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing",
        "id": 133633050,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.",
        "url": "https://finnhub.io/api/news?id=b0a364ba6bee873340f902350d7509fb0e4322e2e929d5e14266bd46254cdae2"
    },
    {
        "category": "company",
        "datetime": 1743427800,
        "headline": "RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar",
        "id": 133627790,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.",
        "url": "https://finnhub.io/api/news?id=2773ab609e61ad22906a0206ba8fbb465ae5eb55308723b21508b88063cb85c5"
    },
    {
        "category": "company",
        "datetime": 1743421260,
        "headline": "Dow's 113-point rally led by gains for shares of Amgen, IBM",
        "id": 133635908,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's 113-point rally led by gains for shares of Amgen, IBM",
        "url": "https://finnhub.io/api/news?id=b1fb324310d32eea420b654186992bd8c2d3679e66c43181f1bbace1b43b05e5"
    },
    {
        "category": "company",
        "datetime": 1743408000,
        "headline": "Amgen: Excellent Buy And Hold For A Volatile Market",
        "id": 133625373,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=b6d643e1c4e21bfac29ba203376af3f793fb7d80465b59acc84050d17347b3e1"
    },
    {
        "category": "company",
        "datetime": 1743306600,
        "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
        "id": 133594341,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205513/image_1322205513.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b"
    },
    {
        "category": "company",
        "datetime": 1743303000,
        "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
        "id": 133590926,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
        "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    },
    {
        "category": "company",
        "datetime": 1743171300,
        "headline": "2 Surefire Dividend Stocks That Could Pay You for Life",
        "id": 133523787,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Dividend investing is an excellent strategy for (at least) two reasons.  Here are two companies that can pull it off: Amgen (NASDAQ: AMGN) and Coca-Cola (NYSE: KO).  Amgen paid its first dividend in 2011.",
        "url": "https://finnhub.io/api/news?id=8e370c6a2f22875278a1ed6eab738cfee02dc971e53047d1c34f55d8d9824326"
    },
    {
        "category": "company",
        "datetime": 1743166877,
        "headline": "2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down",
        "id": 133508614,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they\u2019ve already captured significant portions of their markets.",
        "url": "https://finnhub.io/api/news?id=af5cdd1563fab45422fe7b0e9ed0ad8f01517b306d766fc600c79ce100018362"
    },
    {
        "category": "company",
        "datetime": 1743166808,
        "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know",
        "id": 133523829,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "url": "https://finnhub.io/api/news?id=976d484c3304ea70d9e10423bd96d577652e493050eed547c901efe7f79c11d8"
    },
    {
        "category": "company",
        "datetime": 1743165000,
        "headline": "Which Dow Jones Stock Is Cheaper, Amgen or Merck?",
        "id": 133508616,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an impressive 21% year to date.  Meanwhile, shares of its pharmaceutical rival Merck (NYSE: MRK) have lagged, down 8% in the same period.  Amgen shareholders are celebrating, but have you wondered which stock is cheaper right now?",
        "url": "https://finnhub.io/api/news?id=2098633fa61e26ac514cdfd5c24d0756e5917dc5dbeb8609a8a0266e0f23e750"
    },
    {
        "category": "company",
        "datetime": 1743085320,
        "headline": "Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.",
        "id": 133481428,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.",
        "url": "https://finnhub.io/api/news?id=f58df00bb20b8c43e492a2a40109df7467ae78a0e89aab182a4cab400cb2a554"
    },
    {
        "category": "company",
        "datetime": 1743078660,
        "headline": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
        "id": 133471694,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
        "url": "https://finnhub.io/api/news?id=20216feaf8f84f97ca0430e38d06cbf894929f9ccb4967c83b027fb867f382eb"
    },
    {
        "category": "company",
        "datetime": 1743060600,
        "headline": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
        "id": 133467152,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=743b5137aca60badcb2ace1e5601b3a1d46e916bce67c484c60523c28bfb157b"
    },
    {
        "category": "company",
        "datetime": 1743060464,
        "headline": "How AZ and Amgen\u2019s Tezspire respiratory data ups the \u2018level of ambition\u2019 in immunology",
        "id": 133468095,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.",
        "url": "https://finnhub.io/api/news?id=001537c9d63008da192689c14cdcb2294b824b9e6b60e58388eb79d4ee37fa02"
    },
    {
        "category": "company",
        "datetime": 1743003900,
        "headline": "As Vaccine Skepticism Mounts, Moderna\u2019s Business Grows More Precarious",
        "id": 134148460,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "As Vaccine Skepticism Mounts, Moderna\u2019s Business Grows More Precarious",
        "url": "https://finnhub.io/api/news?id=7327a14ebc0c7ec414851bb1d083399592dbb1489f8335c450d63df7561aa2dd"
    },
    {
        "category": "company",
        "datetime": 1742920500,
        "headline": "Amgen Inc. stock underperforms Tuesday when compared to competitors",
        "id": 133451251,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Tuesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=f5f9b023f465a34d88f50e212e011c7f858568ebb1281c490d703900cc4c6fb5"
    },
    {
        "category": "company",
        "datetime": 1742912096,
        "headline": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
        "id": 133448536,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
        "url": "https://finnhub.io/api/news?id=d26e7f58a653e3fd29bc58e94abb039bec22520071ab0039419d4d6a620439f6"
    },
    {
        "category": "company",
        "datetime": 1742853014,
        "headline": "Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note",
        "id": 133360414,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.",
        "url": "https://finnhub.io/api/news?id=5f42993740eba8c1cbad0d713447bb438c04d34a8e39ace9417ea66afa6ae8f9"
    },
    {
        "category": "company",
        "datetime": 1742752036,
        "headline": "Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in?",
        "id": 133337916,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best healthcare dividend stocks to invest in. The US healthcare sector has been at the forefront since the emergence of COVID-19 in 2020, [\u2026]",
        "url": "https://finnhub.io/api/news?id=496ceccdea29399882a353685d227806896171d439a76b063952aefeb3316730"
    },
    {
        "category": "company",
        "datetime": 1742577389,
        "headline": "Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth",
        "id": 133310796,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462296278/image_1462296278.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic partnerships positioning it as a 2025 Buy.",
        "url": "https://finnhub.io/api/news?id=4ae28630494687c056f1f1d8d1efc96c72e398f9bc47178cceda8fb21a5f48dd"
    },
    {
        "category": "company",
        "datetime": 1742566206,
        "headline": "Why Amgen (AMGN) is a Top Value Stock for the Long-Term",
        "id": 133325057,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "url": "https://finnhub.io/api/news?id=bc435f61aa10924497a04aa8d0ce921ea1e220bcada936410269884c86e02c80"
    },
    {
        "category": "company",
        "datetime": 1742563852,
        "headline": "3 of Goldman Sachs' best investing tips for currently volatile markets",
        "id": 133311382,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Volatile times in markets require precision, Goldman Sachs reminds investors.",
        "url": "https://finnhub.io/api/news?id=53de6c4e268d53424f20d6ebfaf8653bf2f6cec39368f385d4a1f70b569e3b67"
    },
    {
        "category": "company",
        "datetime": 1742541707,
        "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
        "id": 133297533,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
        "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    },
    {
        "category": "company",
        "datetime": 1742402373,
        "headline": "Stock Market Today: Nasdaq Jumps On Subtle Fed Policy Shift; Dow Up 383 Points, Aims To Retake Key Chart Level (Live Coverage)",
        "id": 133264238,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Stock Market Today: Nasdaq Jumps On Subtle Fed Policy Shift; Dow Up 383 Points, Aims To Retake Key Chart Level (Live Coverage)",
        "url": "https://finnhub.io/api/news?id=e270d327e3cab83cfcf33a848c7162cbf52f74e3bf5fd1bdfb3f2ab0831576eb"
    },
    {
        "category": "company",
        "datetime": 1742397180,
        "headline": "FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review",
        "id": 133325059,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.",
        "url": "https://finnhub.io/api/news?id=680e92563ff55e9cf92e684f269a9a0f0ecfe386216b43ca15b520979fde53b7"
    },
    {
        "category": "company",
        "datetime": 1742334616,
        "headline": "Why the Market Dipped But Amgen (AMGN) Gained Today",
        "id": 133325060,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.",
        "url": "https://finnhub.io/api/news?id=8c874c90529e381c534223c4e583cea542e260cd85228778254eb212270f5578"
    },
    {
        "category": "company",
        "datetime": 1742312940,
        "headline": "Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?",
        "id": 133325061,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.",
        "url": "https://finnhub.io/api/news?id=edcc5e001a1947ec8ec0ac6af5efba0d73bd69847c412e40bddc011ea0042775"
    },
    {
        "category": "company",
        "datetime": 1742305980,
        "headline": "Prediction: These 2 Stocks Will Outperform the Market Through 2030",
        "id": 133324996,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The more we extend our horizon, the more likely it is that stocks will provide juicy returns.  Leading drugmaker Amgen could have several growth drivers through the end of the decade.  Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.",
        "url": "https://finnhub.io/api/news?id=f2fe6063b8313c9d93534b9c548fe38e8aaed476bd5c96097b541a07cb456c69"
    },
    {
        "category": "company",
        "datetime": 1742301600,
        "headline": "Dividend Income: Lanny's February 2025 Summary",
        "id": 133230615,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=96254f82b04f4fa52f3d90b4b63f1b9618a359eb435b95d2add8977c4b53ce4b"
    },
    {
        "category": "company",
        "datetime": 1742290469,
        "headline": "Amgen Inc. (AMGN): Among the Best Biotech Stocks to Buy According to Billionaires",
        "id": 133325063,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best biotech stocks. Although biotech stocks had a \u201cchallenging\u201d year in 2024, JPMorgan believes that some of the industry\u2019s companies could [\u2026]",
        "url": "https://finnhub.io/api/news?id=8f3781d34c474fc00ac2c84803d999adbb1d239354d9e6ca013af6ce9b8476c2"
    },
    {
        "category": "company",
        "datetime": 1742252303,
        "headline": "Why Organon Is A Top Pick For Income Investors",
        "id": 133211092,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472143072/image_1472143072.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
        "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96"
    },
    {
        "category": "company",
        "datetime": 1742248814,
        "headline": "Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider",
        "id": 133325064,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=39a7526e301ae46718f93ca90446d42e78c0cf2243de614387f1f7b888401add"
    },
    {
        "category": "company",
        "datetime": 1742229240,
        "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
        "id": 133215119,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
        "url": "https://finnhub.io/api/news?id=b84354278886d46450c4886dc57317fd75b574e723fd3f35db099d58b77c4635"
    },
    {
        "category": "company",
        "datetime": 1742227500,
        "headline": "AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study",
        "id": 133325065,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.",
        "url": "https://finnhub.io/api/news?id=9d033066f1282fe2483d1e26fd1f36d59fa00dafcbd8aa32ca43a0dbbfb9afa4"
    },
    {
        "category": "company",
        "datetime": 1742216408,
        "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It",
        "id": 133325066,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "url": "https://finnhub.io/api/news?id=bdfeb9beaa5a242e130638f4a41702c3522cf3ec9a72f80abdd96291ccf21bf9"
    },
    {
        "category": "company",
        "datetime": 1742201688,
        "headline": "OPKO and Entera partner to develop obesity pill",
        "id": 133206896,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "OPKO Health and Entera Bioare partnering to develop a once-daily pill forpatients with obesity and other disorders, the companies said onMonday. WHY IT'S IMPORTANT ...",
        "url": "https://finnhub.io/api/news?id=5c63763b0ab32e90c83586839b726eeaa3d77ccc6d41551b2fe8ee4d587323d0"
    },
    {
        "category": "company",
        "datetime": 1742132403,
        "headline": "Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'",
        "id": 133183958,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1494495584/image_1494495584.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover why Johnson & Johnson and Kenvue offer resilient defensive stocks with high dividends.",
        "url": "https://finnhub.io/api/news?id=0e2a33e42c67c50b9950b3dc91a0d5278a086f640ec0823eadf61648f4b4a945"
    },
    {
        "category": "company",
        "datetime": 1741975011,
        "headline": "CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation",
        "id": 133175195,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "March 14 - * CMS: DEALS SIGNED WITH MANUFACTURERS OF 15 DRUGS COVEREDUNDERMEDICARE PART D SELECTED FOR SECOND CYCLE OF MEDICARE DRUG PRICENEGOTIATION PROGRAM ...",
        "url": "https://finnhub.io/api/news?id=9ab3d8ef646f1da11ca00a4ee1d9b52751ab4c4c677a8fbbcef5020b2a4b4f34"
    },
    {
        "category": "company",
        "datetime": 1741968914,
        "headline": "Amgen data \u2018muddies\u2019 outlook for Cartesian, says Oppenheimer",
        "id": 133185002,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company\u2019s Q4 report. The company\u2019s Phase 3 trial in myasthenia gravis remains on track to start by mid-year, the analyst tells investors in a research note. The firm thinks the trial has a \u201cdecent chance at working,\u201d but does not currently view Descartes-08 as a commercially viable therapy. Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six mo",
        "url": "https://finnhub.io/api/news?id=63ea05795c05ca2dc829282a0050debad24683bf6e4645b656f89a6c16a157e3"
    },
    {
        "category": "company",
        "datetime": 1741950022,
        "headline": "AMGEN - UPLIZNA SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
        "id": 133169280,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS - Amgen today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA in adults living with generalized myasthenia gravis .The...",
        "url": "https://finnhub.io/api/news?id=d2785eea749feebe4c745eb96ad3e586fb8742f8106763a10d450687d399cdaa"
    },
    {
        "category": "company",
        "datetime": 1741945228,
        "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
        "id": 133168922,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
        "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c"
    },
    {
        "category": "company",
        "datetime": 1741887066,
        "headline": "Amgen\u2019s gMG therapy cuts disease symptoms at one-year mark",
        "id": 133185003,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Results from the company\u2019s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom impact.",
        "url": "https://finnhub.io/api/news?id=529e178c0165fe3707221cd3f527ab8d73217040dbe8c4350f7fc40e557d5b4b"
    },
    {
        "category": "company",
        "datetime": 1741886479,
        "headline": "Amgen (NasdaqGS:AMGN) Announces Promising MINT Trial Data For UPLIZNA In Generalized Myasthenia Gravis",
        "id": 133185004,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating generalized myasthenia gravis, likely influencing its 14% price increase over the last quarter. These findings, emphasizing the drug's efficacy, coincide with Amgen's Q4 2024 earnings report, which showed a rise in revenue yet a decline in net income, reflecting a mixed financial performance. Despite the broader stock market experiencing declines, with the S&P 500 and...",
        "url": "https://finnhub.io/api/news?id=185b1b7e5403923af9a7b61a73d433af8b0629169469cfa68a655101c4bc05bc"
    },
    {
        "category": "company",
        "datetime": 1741882159,
        "headline": "Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds?",
        "id": 133185005,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in the [\u2026]",
        "url": "https://finnhub.io/api/news?id=ad584a1229bea742457490e2e724913403c2596cf3542de599d0906fa8b77253"
    },
    {
        "category": "company",
        "datetime": 1741880186,
        "headline": "Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year",
        "id": 133185006,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. It affects the muscles used for breathing, swallowing, facial expressions, and movement. The results demonstrated the durable and sustained efficacy of Uplizna in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year following",
        "url": "https://finnhub.io/api/news?id=df93a46db57475cf1e1d6e4bfbd1cbb495eb834505cdf3a71e6f34e328cfb387"
    },
    {
        "category": "company",
        "datetime": 1741879829,
        "headline": "Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?",
        "id": 133185007,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=ab3e6ced87929751718f055d8a160a40869f78e27b165e7d9e973304a0feef4f"
    },
    {
        "category": "company",
        "datetime": 1741874303,
        "headline": "Amgen Says Phase 3 Data Support Uplizna's Efficacy in Generalized Myasthenia Gravis",
        "id": 133185008,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) said Thursday said that a phase 3 trial of its Uplizna drug showed \"durable and sustain",
        "url": "https://finnhub.io/api/news?id=480b83dd43e9ceeedcd19f525459fd1a55406a1dd6164042b856b748adcb6069"
    },
    {
        "category": "company",
        "datetime": 1741873807,
        "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
        "id": 133185009,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=d7bb7225c373d9ec0dbb2bde60b5846429726c47e990e017169b565bb62a5c3e"
    },
    {
        "category": "company",
        "datetime": 1741870800,
        "headline": "UPLIZNA\u00ae (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS",
        "id": 133185010,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA\u00ae (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results demonstrated durable and sustained efficacy of UPLIZNA in patients with acetylcholine receptor autoantibody-positive (AChR+) gMG with two doses a year, following an initial loading dose. Findings will be presented as a late-breaking oral presentation during the American Ac",
        "url": "https://finnhub.io/api/news?id=5756459ee02a0272ebc14702b0f097906e2b590c22b5fd744bb9b7bf6e57aff6"
    },
    {
        "category": "company",
        "datetime": 1741863142,
        "headline": "Uplizna Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-Positive Patients Over 52 Weeks",
        "id": 133162804,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Amgen Inc: * UPLIZNA\u00ae SIGNIFICANTLY IMPROVESGENERALIZEDMYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTORAUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS * AMGEN INC: NO...",
        "url": "https://finnhub.io/api/news?id=29f431b2a22132e350e480f60777ebbe838c5630f9976cd7aac4c0e75b21a0c9"
    },
    {
        "category": "company",
        "datetime": 1741788283,
        "headline": "Amgen Inc. (AMGN): Among Dobermans of the Dow to Buy",
        "id": 133185011,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of the Dow [\u2026]",
        "url": "https://finnhub.io/api/news?id=586472abd408288e0b41438b01c1a3831c685cf4b0162f5cdf215f98a07ebec4"
    },
    {
        "category": "company",
        "datetime": 1741777020,
        "headline": "Verizon, McDonald's share losses lead Dow's 313-point drop",
        "id": 133150310,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Verizon, McDonald's share losses lead Dow's 313-point drop",
        "url": "https://finnhub.io/api/news?id=a2e8622b35c3e738721cfee729bf42cc53e7838f4c24db44664dcf43d6e1b30f"
    },
    {
        "category": "company",
        "datetime": 1741774002,
        "headline": "Dow's relief rally quickly fades. Here are some key stocks dragging it down.",
        "id": 133151061,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's relief rally quickly fades. Here are some key stocks dragging it down.",
        "url": "https://finnhub.io/api/news?id=a9f2657ca724aeb62bc52582693a4465dcd4268415af48a4ba5ce5b253e5da4c"
    },
    {
        "category": "company",
        "datetime": 1741773360,
        "headline": "Verizon, Amgen share losses lead Dow's nearly 150-point fall",
        "id": 133151062,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Verizon, Amgen share losses lead Dow's nearly 150-point fall",
        "url": "https://finnhub.io/api/news?id=045d6fb7b4d7b1e92fc920991af21358b92de7cb9be70ed19b8bb77041d70566"
    },
    {
        "category": "company",
        "datetime": 1741707608,
        "headline": "HALO vs. AMGN: Which Stock Is the Better Value Option?",
        "id": 133185012,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "HALO vs. AMGN: Which Stock Is the Better Value Option?",
        "url": "https://finnhub.io/api/news?id=e1b2af28f7676fa027e587a48699b9194a5618d140bb627a6b91100685e89aa5"
    },
    {
        "category": "company",
        "datetime": 1741700400,
        "headline": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "id": 133136678,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "These 10 stocks beating the market\u2019s recent Trump slump have this in common",
        "url": "https://finnhub.io/api/news?id=e8383f6a57268bab0c9cf132cc1de00ab367c29c1676d860b3901c1a8d646442"
    },
    {
        "category": "company",
        "datetime": 1741698125,
        "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
        "id": 133136036,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    },
    {
        "category": "company",
        "datetime": 1741666090,
        "headline": "Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 And Anti-CTLA-4 Antibody Combination Method Of Treatment Patents",
        "id": 133130479,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "On February 28, Amgen, Inc. filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. . The claims of all three...",
        "url": "https://finnhub.io/api/news?id=24ef298c271873f3a1466ab7d51933f551422d33d5a15e6519fbf7ec05a746d3"
    },
    {
        "category": "company",
        "datetime": 1741630632,
        "headline": "Stock market sell-off: Why these stocks are in the green amid the pain",
        "id": 133184559,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The shift to defense is on.",
        "url": "https://finnhub.io/api/news?id=b4817b2db1f2b2841b7c6941f4f1d8c6378ba55c52a7c3036a715bd6ab90bb31"
    },
    {
        "category": "company",
        "datetime": 1741625200,
        "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
        "id": 133127786,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220400589/image_1220400589.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    },
    {
        "category": "company",
        "datetime": 1741621324,
        "headline": "Amgen : Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products",
        "id": 133125713,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
        "url": "https://finnhub.io/api/news?id=4f36151ad6c811da06182b548d3769fb6f8924626ca5419c49780b2c29b9421f"
    },
    {
        "category": "company",
        "datetime": 1741613220,
        "headline": "AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies",
        "id": 133185014,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.",
        "url": "https://finnhub.io/api/news?id=58ef0150b41d2233a520d9bd77af4d5b028c9786dd73f802323e68c42b56be10"
    },
    {
        "category": "company",
        "datetime": 1741610357,
        "headline": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
        "id": 133122070,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS, TOKYO - Amgen and Kyowa Kirin Co., Ltd. today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell...",
        "url": "https://finnhub.io/api/news?id=9f19f7cbf57d1b3d4633eaa509b89e40e9ceba9443c1c02f5b391929fe87e35a"
    },
    {
        "category": "company",
        "datetime": 1741606232,
        "headline": "Amgen and Kyowa Kirin\u2019s rocatinlimab trial for atopic dermatitis meets endpoints",
        "id": 133185015,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "All the key secondary endpoints of the trial were met, demonstrating the \u201cstatistical significance\u201d of the therapy.",
        "url": "https://finnhub.io/api/news?id=02e3b86c71c90876f8699724049e65d0639a7cf7d52e91575d0f4a6016284b82"
    },
    {
        "category": "company",
        "datetime": 1741602900,
        "headline": "Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus",
        "id": 133185016,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.",
        "url": "https://finnhub.io/api/news?id=cd3c8dc42f251d0f61122a72c4eecd5eaf425f1142d318169c9f4cfd57c4a4b6"
    },
    {
        "category": "company",
        "datetime": 1741448460,
        "headline": "3 Magnificent Growth Stocks to Buy in March",
        "id": 133185017,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry.  With that context in mind, consider that Eli Lilly's revenue growth has not dipped below 20% since mid-2023.",
        "url": "https://finnhub.io/api/news?id=b9e2ea71c875b99b34fdb720c216a37bf14fa2904bbfc4b0be137be181e6570e"
    },
    {
        "category": "company",
        "datetime": 1741431600,
        "headline": "A Major Market Rotation Is Likely Coming",
        "id": 133107060,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2151843291/image_2151843291.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The market hasn\u00e2\u0080\u0099t priced in several undervalued AI stocks. Read why these stocks could outperform tech in the next market cycle.",
        "url": "https://finnhub.io/api/news?id=1c6d6c18c949ac77909a5de381dc8c854be2e40d9ba7d6a9459ec91dbff1bf7c"
    },
    {
        "category": "company",
        "datetime": 1741365062,
        "headline": "Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?",
        "id": 133185019,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
        "url": "https://finnhub.io/api/news?id=c476aade2932654a33c27695e4be94241e12fc7fccb1a6936e4fe75a02939bc3"
    },
    {
        "category": "company",
        "datetime": 1741362180,
        "headline": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
        "id": 133104926,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's nearly 150-point rally led by gains in IBM, Verizon stocks",
        "url": "https://finnhub.io/api/news?id=9d8713d3a0ffcd0a062f0d98ece59bf2bb2f4cf651d9890109a72c5bf342d5a2"
    },
    {
        "category": "company",
        "datetime": 1741358340,
        "headline": "IBM, Verizon share gains lead Dow's 250-point jump",
        "id": 133104927,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "IBM, Verizon share gains lead Dow's 250-point jump",
        "url": "https://finnhub.io/api/news?id=9d397a9f8dd02ce2fcd406ef21d6f116a2e8b3c1c1c4228aaeb8f1fe9362f7e4"
    },
    {
        "category": "company",
        "datetime": 1741354680,
        "headline": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
        "id": 133104692,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's 114-point rally highlighted by gains in IBM, Verizon shares",
        "url": "https://finnhub.io/api/news?id=157d95000339e52076b0a32a2d09b6585f542f1c7fb8be751bda170684a6bb5a"
    },
    {
        "category": "company",
        "datetime": 1741348800,
        "headline": "Recession Risk And Pockets Of Strength",
        "id": 133092602,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1201610071/image_1201610071.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Budweiser keeps pushing higher. AI segments moving down. Bitcoin in short and long-term. Economy not looking as sweet.",
        "url": "https://finnhub.io/api/news?id=68f875920374e19e623e7f3d76e7b8a2c5d5fa48c455f322084e0817d8cfe62b"
    },
    {
        "category": "company",
        "datetime": 1741341780,
        "headline": "2 Dividend Stocks to Buy for a Lifetime of Passive Income",
        "id": 133185020,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Dividend investors don't buy shares of companies hoping they will suspend their payouts soon.  The longer a corporation maintains its dividend program, the more attractive it is to income seekers, all else being equal.  Let's discuss two that have what it takes to pay investors regular dividends for good: Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV).",
        "url": "https://finnhub.io/api/news?id=68e6f0a6f97e943f5b93938ce6707ef21444de09ae23e8101973d69abd49fa67"
    },
    {
        "category": "company",
        "datetime": 1741341600,
        "headline": "Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup",
        "id": 133185021,
        "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. And Big Pharma is lobbying for a tax break that would have saved it at least $15 billion in 2023.",
        "url": "https://finnhub.io/api/news?id=9a2bbef40445bd567ecef788723d52383eef021996c7d869bbb90c819cd5c76f"
    },
    {
        "category": "company",
        "datetime": 1741189140,
        "headline": "Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out",
        "id": 134146993,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out",
        "url": "https://finnhub.io/api/news?id=3440ff10a59f58a05553b64b29e518edc846c32ab72cf2f47c6b2022112b2d7f"
    },
    {
        "category": "company",
        "datetime": 1741181460,
        "headline": "5 Big Biopharmaceutical Stocks That Are Finding Favor",
        "id": 133017083,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "5 Big Biopharmaceutical Stocks That Are Finding Favor",
        "url": "https://finnhub.io/api/news?id=26ee08ddf101d2a804ccb3de6ef47bdd041f08f4c18732bc711d2fb938484324"
    },
    {
        "category": "company",
        "datetime": 1741172944,
        "headline": "Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript)",
        "id": 133015707,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive Vice...",
        "url": "https://finnhub.io/api/news?id=e52089766d7f6c90cafb8e2700da00f28594776be8ec5e51fdb622116bf2ca65"
    },
    {
        "category": "company",
        "datetime": 1741107365,
        "headline": "AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND",
        "id": 132980532,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on...",
        "url": "https://finnhub.io/api/news?id=10fb504145b7251ed112b480d072b99963a00528335899cd8bcd46556f756f3a"
    },
    {
        "category": "company",
        "datetime": 1741100163,
        "headline": "Dogs Of The Dow Chase A \"Safer\" Buy For March",
        "id": 132979830,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173947104/image_173947104.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "My monthly update and commentary on the top dividend stock picks from the Dogs Of The Dow, March 2025 edition. Click here to read more about Dogs of the Dow.",
        "url": "https://finnhub.io/api/news?id=cc6dd860b385b0d72b9bb16ee9ff5ee719c89916be0857afbb145306c6255282"
    },
    {
        "category": "company",
        "datetime": 1740999561,
        "headline": "AMGEN - POSITIVE RESULTS FROM TEZSPIRE PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",
        "id": 132954284,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS - Amgen and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly reduced nasal polyp severity, the need...",
        "url": "https://finnhub.io/api/news?id=0b3cba3af4c73ad515039f3b29a898f7da41832d0ff9060bda05446e9c88d6f4"
    },
    {
        "category": "company",
        "datetime": 1740885493,
        "headline": "AstraZeneca, Amgen drug shows positive results in nasal polyps trials",
        "id": 132941804,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "An asthma drug has shown positive results when used to treat nasal polyps, researchers have said.Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of...",
        "url": "https://finnhub.io/api/news?id=e8771c1ed53892f4831fae9aa46aa640f340d69cd78654717a84e4ce6f26b4dc"
    },
    {
        "category": "company",
        "datetime": 1740788508,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of March 2",
        "id": 132923903,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Read here for key dividend updates for Dividend Champions, Contenders, and Challengers. Learn about changes, ex-dividend dates, & payment schedules.",
        "url": "https://finnhub.io/api/news?id=87534fcd5ea5e44020a508adb3e369e09ef27091eed37edf1e300f8cdf6e062d"
    },
    {
        "category": "company",
        "datetime": 1740758524,
        "headline": "AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE",
        "id": 132915273,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ --\u00a0Amgen will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner, executive vice...",
        "url": "https://finnhub.io/api/news?id=af82d6dbfc36a6e8048cf7f157baff7d71118649083a4f8f9b2b739e26476e3f"
    },
    {
        "category": "company",
        "datetime": 1740726000,
        "headline": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "id": 132907806,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Drug Stocks Are the New Safe Bet in a Shaky Market",
        "url": "https://finnhub.io/api/news?id=9cbf52ef07edbc5bfcfb2610a217677b7f12f0522f3e65f5864ff7326854f3b8"
    },
    {
        "category": "company",
        "datetime": 1740582780,
        "headline": "Apple, Amgen share losses lead Dow's 175-point drop",
        "id": 132881137,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Apple, Amgen share losses lead Dow's 175-point drop",
        "url": "https://finnhub.io/api/news?id=7e25b1270deb7026de6b6b34b197b6c67acfb06bf1c29aaf9f0189d9baa3ae69"
    },
    {
        "category": "company",
        "datetime": 1740578220,
        "headline": "Boeing, Apple share losses lead Dow's 289-point drop",
        "id": 132881138,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Boeing, Apple share losses lead Dow's 289-point drop",
        "url": "https://finnhub.io/api/news?id=8d5e76ddd9b6246d79b92079eb11f2b417b104f10a3350efd56591f7449c19b4"
    },
    {
        "category": "company",
        "datetime": 1740574560,
        "headline": "Dow falls 110 points on losses for Boeing, Amgen shares",
        "id": 132881139,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow falls 110 points on losses for Boeing, Amgen shares",
        "url": "https://finnhub.io/api/news?id=0c818dab1edd19660f0d68c466c099a114115cbcf0d50af0a1123c1a58cc8252"
    },
    {
        "category": "company",
        "datetime": 1740573110,
        "headline": "Amgen Stock: Why I Still Rate It A 'Buy'",
        "id": 132879319,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227488268/image_1227488268.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "In early February, Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.",
        "url": "https://finnhub.io/api/news?id=a057b459a23ece013b3cf450ae99f06fa5266ecf0435294fd851d9d2fad22c4b"
    },
    {
        "category": "company",
        "datetime": 1740496800,
        "headline": "Walmart, Home Depot share gains contribute to Dow's 236-point climb",
        "id": 132881889,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Walmart, Home Depot share gains contribute to Dow's 236-point climb",
        "url": "https://finnhub.io/api/news?id=e023b6578b940024f7b428d23001d3302559880734b587eb9555b29673277bd2"
    },
    {
        "category": "company",
        "datetime": 1740487380,
        "headline": "Home Depot, Walmart share gains contribute to Dow's 118-point climb",
        "id": 132881890,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Home Depot, Walmart share gains contribute to Dow's 118-point climb",
        "url": "https://finnhub.io/api/news?id=23886a01e0e97de982f764d310e57b084be68ad289ffcde3906a14232bfd205d"
    },
    {
        "category": "company",
        "datetime": 1740474000,
        "headline": "10 Undervalued Dividend Growth Stocks: February 2025",
        "id": 132870866,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=712bdbf6ff26876ba20b43ef010c2f165ae8a0261b7c844089b2f5a9c9a4686a"
    },
    {
        "category": "company",
        "datetime": 1740410880,
        "headline": "Nike, Travelers share gains contribute to Dow's 131-point climb",
        "id": 132882872,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Nike, Travelers share gains contribute to Dow's 131-point climb",
        "url": "https://finnhub.io/api/news?id=41b3d6a47aa84c030e1b15b25b408370b1304abdad9250a27c6d06e7428d00b4"
    },
    {
        "category": "company",
        "datetime": 1740401100,
        "headline": "Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers",
        "id": 132882559,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's nearly 250-point rally highlighted by gains in shares of Nike, Travelers",
        "url": "https://finnhub.io/api/news?id=643b1b6d862bc3c25da0a4bdeee480f03468550f94d7c435a8b445b55d04ec75"
    },
    {
        "category": "company",
        "datetime": 1740396000,
        "headline": "Nike, Travelers share gains contribute to Dow's nearly 125-point climb",
        "id": 132882560,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Nike, Travelers share gains contribute to Dow's nearly 125-point climb",
        "url": "https://finnhub.io/api/news?id=de434551e8d9bd44a812478e4f9b5a4e3b1e915e3acb46821e8664bdc3ba1be4"
    },
    {
        "category": "company",
        "datetime": 1740386100,
        "headline": "Columbia Flexible Capital Income Fund Q4 2024 Commentary",
        "id": 132863438,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1469297427/image_1469297427.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Columbia Flexible Capital Income Fund Institutional Class shares returned -0.67% in Q4 2024. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=bed3c127639568578a31cfd8198cfd15317262fdcc9c2dd97e63c35ea5206e35"
    },
    {
        "category": "company",
        "datetime": 1740360506,
        "headline": "Amgen plans $200 million investment in India site, CEO says",
        "id": 132861119,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the...",
        "url": "https://finnhub.io/api/news?id=d387083a1d74aa39c55c1c95f9e360a79c36e61ddde778b1c6794e056ab2383e"
    },
    {
        "category": "company",
        "datetime": 1740005164,
        "headline": "Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)",
        "id": 132792663,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen, Inc. (NASDAQ:AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ETCompany ParticipantsJean-Charles Soria...",
        "url": "https://finnhub.io/api/news?id=1e09f4612f8eb2c1c63bf2dd01cbf6170fada9228cd8b89143f3ef1b09eeece4"
    },
    {
        "category": "company",
        "datetime": 1739934600,
        "headline": "Aristotle Global Equity Q4 2024 Commentary",
        "id": 132782563,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193247114/image_2193247114.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "For Q4 2024, Aristotle Capital\u00e2\u0080\u0099s Global Equity Composite posted a total return of -7.72% gross of fees (-7.80% net of fees). Click here to read more.",
        "url": "https://finnhub.io/api/news?id=c0014d4bc8368d4fab1e7fbb5365a9e3aa0f99d91a921306589705534fa598ab"
    },
    {
        "category": "company",
        "datetime": 1739870341,
        "headline": "Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib",
        "id": 132767396,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=d8b1d0947d6754829b3abbb94e80bbadea9c4acd10a9ff06e54d3bb5d6eded71"
    },
    {
        "category": "company",
        "datetime": 1739742843,
        "headline": "Why Regeneron's Price May Soon Break Out",
        "id": 132742765,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.",
        "url": "https://finnhub.io/api/news?id=d5af37c15f7937cb7659c25bbaefc15e6d819270430ea1e30992e3c141a5a315"
    },
    {
        "category": "company",
        "datetime": 1739552936,
        "headline": "SCHD Is So Boring, And Big Changes Are In Store",
        "id": 132713528,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2171261686/image_2171261686.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The Schwab U.S. Dividend Equity ETF is a top pick for conservative investors seeking stable returns & dividend growth. Click here to read why SCHD ETF is a Buy.",
        "url": "https://finnhub.io/api/news?id=4080ed02c3ced07df338391ca213f9dc6c12aaae975c352a85b703d6f8728141"
    },
    {
        "category": "company",
        "datetime": 1739550900,
        "headline": "Amgen Inc. stock underperforms Friday when compared to competitors",
        "id": 132722048,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Friday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=0614be864beadfb8235d2ba0def29fa4f677c5603c1a01d4e3c1e2dd8c599a80"
    },
    {
        "category": "company",
        "datetime": 1739480280,
        "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q4 2024 Commentary",
        "id": 132709614,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172483014/image_172483014.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The Portfolio returned -10.75% (gross) and the MSCI World Health Care IndexSM returned -11.32%. Read more here.",
        "url": "https://finnhub.io/api/news?id=8d306981723ae6baaa27a41df72a2ad77528d2ff9fae45eee20d34b6483d2dcd"
    },
    {
        "category": "company",
        "datetime": 1739468968,
        "headline": "Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain",
        "id": 132709074,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Kiniksa Pharmaceuticals stock is attractive because it trades near 52-week lows, and its marketed drug gains traction. Click to find out why KNSA is a Hold.",
        "url": "https://finnhub.io/api/news?id=5d90ca30706ab51288585963e09287df18a5bd0de91ce97d5e6f55d739ca71ee"
    },
    {
        "category": "company",
        "datetime": 1739392800,
        "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
        "id": 132698753,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
        "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    },
    {
        "category": "company",
        "datetime": 1739377566,
        "headline": "IGA: Good Diversification And Fully-Covered Distribution (Rating Upgrade)",
        "id": 132689669,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302522750/image_1302522750.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Voya Global Advantage and Premium Opportunity Fund has a 10.74% yield, diversification benefits, and well-covered distributions. Click for my IGA CEF update.",
        "url": "https://finnhub.io/api/news?id=2ba8d05d868d19834abb8a5b6fdaa46772c05175fc15d368f4cc2a0552dcd71b"
    },
    {
        "category": "company",
        "datetime": 1739373724,
        "headline": "Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript",
        "id": 132685933,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen, Inc. (NASDAQ:AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ETCompany ParticipantsNarimon...",
        "url": "https://finnhub.io/api/news?id=89999aebb4fc10324384eedd58042dd814bdec10a29d8ebdf6531db756be1e50"
    },
    {
        "category": "company",
        "datetime": 1739287332,
        "headline": "Mereo BioPharma: Good Science, Fairly Valued",
        "id": 132674083,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.",
        "url": "https://finnhub.io/api/news?id=aac5001ee3c68abbe0fdbdbe75a1a670cd92770cffba165941175618df074c03"
    },
    {
        "category": "company",
        "datetime": 1739238000,
        "headline": "Steady M&A Deals To Begin 2025, Disappointing IPOs So Far",
        "id": 132656392,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912015742/image_912015742.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.",
        "url": "https://finnhub.io/api/news?id=672b6866755d06c6e531c019654992d06ff098e491e3acc23ca6d5923d328a83"
    },
    {
        "category": "company",
        "datetime": 1739205407,
        "headline": "Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming",
        "id": 132638958,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192903839/image_2192903839.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Explore the potential of Ideaya Biosciences, Inc.'s Darovasertib in treating uveal melanoma as a monotherapy and in combination therapy. Click for more on IDYA.",
        "url": "https://finnhub.io/api/news?id=58cf062de0b62a43333be43bed26cf79b7dd57ae23ace8f7c108b7af4f624e8e"
    },
    {
        "category": "company",
        "datetime": 1739161367,
        "headline": "Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns",
        "id": 132630802,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1981445243/image_1981445243.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a great buy on dips if they happen.",
        "url": "https://finnhub.io/api/news?id=c0e0ecb614e76b2df98ece704c0f97ce2b3cf6581e379151c4c6916306e2957d"
    },
    {
        "category": "company",
        "datetime": 1739002500,
        "headline": "Funds Only SWAN Retirement Portfolio: $6,000 Monthly Income",
        "id": 132603018,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=340915c44dabc029c5941f4a424d90f5a0da31fe20d57bdfb8454ad30fe66cbc"
    },
    {
        "category": "company",
        "datetime": 1739001261,
        "headline": "One 'Safer' Buy In 10 February Dogs Of The Dow",
        "id": 132602946,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839458057/image_1839458057.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Verizon's dividend yield and Merck\u00e2\u0080\u0099s growth lead the Dow Dogs. Read why they\u00e2\u0080\u0099re set for solid returns, with other top picks closely following in February 2026.",
        "url": "https://finnhub.io/api/news?id=14b4128129dde93c0054cd30e448c400a14d653d5137e8f85fb50551b472f598"
    },
    {
        "category": "company",
        "datetime": 1738989856,
        "headline": "Terns Pharma: I Don't See The Positioning",
        "id": 132602285,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.",
        "url": "https://finnhub.io/api/news?id=dc255b053659bc4f6cd28a060f13a5c868e08359ca7778dd47f694cdbf82b323"
    },
    {
        "category": "company",
        "datetime": 1738980015,
        "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 9",
        "id": 132601739,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Stay informed on the latest dividend activity for top companies with this weekly summary. Read more here.",
        "url": "https://finnhub.io/api/news?id=450fdd4915daefa4b2d863ad148618665374525f5d5fa3e8a28182ab7e73729d"
    },
    {
        "category": "company",
        "datetime": 1738931400,
        "headline": "AI Earnings, Tariff Threats, And Other Bellwether Stocks",
        "id": 132598762,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182177306/image_182177306.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Palantir's soaring but concerns remain. Tariff threats and bellwether earnings.",
        "url": "https://finnhub.io/api/news?id=f3aeea1ec6416aa7f6fd41283be152445518dcebff8d9abe11342941b513e9be"
    },
    {
        "category": "company",
        "datetime": 1738923524,
        "headline": "23 Upcoming Dividend Increases, Including 2 Kings",
        "id": 132598253,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1198972656/image_1198972656.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover the latest dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=49ded6e14a6f99677cd4964e5dd81802778752617f9d35d43fb53cc870ebc5dc"
    },
    {
        "category": "company",
        "datetime": 1738901479,
        "headline": "Amgen: Multiple Strengths, But The Valuation Is A Concern",
        "id": 132596980,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=1c67a453140580091add567433e26bfec747d2982ef03cbaa99de51f07a5da7e"
    },
    {
        "category": "company",
        "datetime": 1738858620,
        "headline": "Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next.",
        "id": 134148466,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Stock Has Surged. Here\u2019s Where It\u2019s Headed Next.",
        "url": "https://finnhub.io/api/news?id=903c377631a8e3dc89ac1a005a7711204e5e2613b0a33eb4ae8d90708713e809"
    },
    {
        "category": "company",
        "datetime": 1738856820,
        "headline": "Dow's 175-point fall led by losses in shares of Honeywell, Salesforce",
        "id": 132581651,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's 175-point fall led by losses in shares of Honeywell, Salesforce",
        "url": "https://finnhub.io/api/news?id=0fc11537943c0917a3e0674a6ea8756e7e546640b21c4c5616558eee7236a341"
    },
    {
        "category": "company",
        "datetime": 1738856375,
        "headline": "Amgen: The Charts Didn't Lie, Upgrade To Buy",
        "id": 132580512,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance. Click to read why AMGN is a Buy.",
        "url": "https://finnhub.io/api/news?id=2b125123865c83fffa9bab15bb071782ab39db0e6942e6e52e1641348a826196"
    },
    {
        "category": "company",
        "datetime": 1738852320,
        "headline": "Dow's nearly 300-point drop led by losses for Honeywell, Salesforce shares",
        "id": 132581652,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's nearly 300-point drop led by losses for Honeywell, Salesforce shares",
        "url": "https://finnhub.io/api/news?id=6df5b890c37a4bda978689993897c29a8d17d2504a64c39d2573a8a7f0436d7a"
    },
    {
        "category": "company",
        "datetime": 1738843920,
        "headline": "Dow's nearly 175-point fall led by losses in Honeywell, Salesforce shares",
        "id": 132573946,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow's nearly 175-point fall led by losses in Honeywell, Salesforce shares",
        "url": "https://finnhub.io/api/news?id=bd03cd1bc072494ba2c04b4183e75fcbe31ee494c6d54af79cd9fe1535377087"
    },
    {
        "category": "company",
        "datetime": 1738827432,
        "headline": "Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)",
        "id": 132572496,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=d7bedba14b1a1994d149b3f7723113d044bf6169c5e2ab5c401e1684bf0cea4c"
    },
    {
        "category": "company",
        "datetime": 1738768125,
        "headline": "Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating",
        "id": 132565449,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.",
        "url": "https://finnhub.io/api/news?id=875a53d3d17f3991b2caeb7e5a5814b08dfee064061d5f713a2aa9203a132a48"
    },
    {
        "category": "company",
        "datetime": 1738764480,
        "headline": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
        "id": 132564061,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow up 264 points on gains for Amgen, NVIDIA Corp. shares",
        "url": "https://finnhub.io/api/news?id=14522b0ead6971c45a7d15acc074a34c685995d64c40e7b4752770b363481809"
    },
    {
        "category": "company",
        "datetime": 1738761030,
        "headline": "Regeneron Is Playing Defense With Capital Allocation",
        "id": 132563616,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2129856936/image_2129856936.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read why I rate REGN a Buy.",
        "url": "https://finnhub.io/api/news?id=9a0c9b25731d76b789ce893a51dade7a12e0b641dc763a1ebb21f152d7bed54c"
    },
    {
        "category": "company",
        "datetime": 1738756320,
        "headline": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
        "id": 132564063,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen, NVIDIA Corp. share gains contribute to Dow's nearly 150-point climb",
        "url": "https://finnhub.io/api/news?id=4cd443e114c79cbc979e50a14141aa0503528955326bdd3ab0714973ab0a7ecc"
    },
    {
        "category": "company",
        "datetime": 1738749881,
        "headline": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
        "id": 132566414,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs",
        "url": "https://finnhub.io/api/news?id=c12b4071d5b7cee405b563bd5a1519bec9dd57d2cabc2b8829e32cee10af15e9"
    },
    {
        "category": "company",
        "datetime": 1738725856,
        "headline": "Amgen: EPS up 13% in Q4",
        "id": 132559616,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Amgen reported adjusted EPS for the last three months of 2024 up 13% to $5.31, with non-GAAP operating margin down 0.4 points to 46.3% but revenues up 11% to $9.1 billion.Product sales were up 11%,...",
        "url": "https://finnhub.io/api/news?id=e686ed39767a22281a563b18f2350ac54aca92a23f7343bdb8a4efefd6b8d17e"
    },
    {
        "category": "company",
        "datetime": 1738701214,
        "headline": "Amgen Inc. 2024 Q4 - Results - Earnings Call Presentation",
        "id": 132558945,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by Amgen Inc.",
        "url": "https://finnhub.io/api/news?id=f839ce2777d24bcf0d39a821b22b7d79e93899a8c5fe659c56de82b5a56e32f7"
    },
    {
        "category": "company",
        "datetime": 1738701152,
        "headline": "Amgen, Inc. (AMGN) Q4 2024 Earnings Call Transcript",
        "id": 132558946,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen, Inc. (NASDAQ:AMGN) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - Chairman,...",
        "url": "https://finnhub.io/api/news?id=aea226cb234b780918e8f21df5dae8eb12b3d5142f6842d31f3a607385a8a4bf"
    },
    {
        "category": "company",
        "datetime": 1738685640,
        "headline": "Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains",
        "id": 132566436,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains",
        "url": "https://finnhub.io/api/news?id=44757ec0ef8f6cd61334b966809982fb11711e78844d466bb908c35d3238209d"
    },
    {
        "category": "company",
        "datetime": 1738648510,
        "headline": "Alphabet results lead busy day of earnings",
        "id": 132543886,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Alphabet results lead busy day of earnings",
        "url": "https://finnhub.io/api/news?id=e5dfd889369f51d42634e6a306820faabbe83decbd89331f4eace874326224f3"
    },
    {
        "category": "company",
        "datetime": 1738573457,
        "headline": "AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS",
        "id": 132520510,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS - Amgen today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets.The...",
        "url": "https://finnhub.io/api/news?id=ac95a84ae9d3e39df7252d37b37f47ef1a81f708ce60cb0fbde970864bc9f6e4"
    },
    {
        "category": "company",
        "datetime": 1738476596,
        "headline": "Wall Street Week Ahead",
        "id": 132514375,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175464726/image_175464726.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Stay informed with the latest financial updates! Get a daily podcast of Wall Street Breakfast on Seeking Alpha, iTunes, and Spotify by 8:00 a.m.",
        "url": "https://finnhub.io/api/news?id=b628db79bec8b4ba19db49d42ef374af40f7c9effdf8a9adc7a8aa86c521dc6d"
    },
    {
        "category": "company",
        "datetime": 1738407600,
        "headline": "Busy Earnings Season Continues With Alphabet, Disney, Palantir To Report Results",
        "id": 132510711,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Tech biggies continue to report earnings this week. A bunch of labor reports are to be released. EU inflation data will be released on Wednesday. See more here.",
        "url": "https://finnhub.io/api/news?id=4183cd54aed2c97e8c317416c61a1ac1dab36e61d22ba5d773abed5f29b17495"
    },
    {
        "category": "company",
        "datetime": 1738320600,
        "headline": "AbbVie Stock Jumps on Earnings and Revenue Beat",
        "id": 132521712,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "AbbVie Stock Jumps on Earnings and Revenue Beat",
        "url": "https://finnhub.io/api/news?id=8863b11c7f9e394aabeaa49332e3a702fd25430f7e6aebf71447a605a81d2afb"
    },
    {
        "category": "company",
        "datetime": 1738256595,
        "headline": "Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)",
        "id": 132501142,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306196820/image_1306196820.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.",
        "url": "https://finnhub.io/api/news?id=dd168be539f783d37d02b1d810048621995d12208ef27c6415a13e9da73898b8"
    },
    {
        "category": "company",
        "datetime": 1738220886,
        "headline": "Correction And Interpretation Of Errors In A Patent At The UPC",
        "id": 132498686,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "In a recent decision, the UPC Court of Appeal ruled on the correction of errors in a patent by interpretation. This case, concerning Alexion Pharmaceuticals' patent , underscores the importance of...",
        "url": "https://finnhub.io/api/news?id=e8e5f8f1a02dad9d49b6c695ddf19050ad80e8fad833d8c642d778d6589709d4"
    },
    {
        "category": "company",
        "datetime": 1738076400,
        "headline": "Drugmakers Show Restraint on Price Increases in New Trump Era",
        "id": 132521086,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Drugmakers Show Restraint on Price Increases in New Trump Era",
        "url": "https://finnhub.io/api/news?id=f17a76ce54722d42e46d57502373ff6b6b7457c0b31bbeec482cfbcfe634f5e6"
    },
    {
        "category": "company",
        "datetime": 1738063664,
        "headline": "Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business",
        "id": 132486768,
        "image": "",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "",
        "url": "https://finnhub.io/api/news?id=a5a4cf9339897bd2d01e23ee2da55475ded2fe272ed446b58300b1db9b8d3158"
    },
    {
        "category": "company",
        "datetime": 1737995760,
        "headline": "Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "id": 132523285,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=82b60ff04b5ec745d7578d7d701de7a44bae6f58910ff3eedb017360a444f33e"
    },
    {
        "category": "company",
        "datetime": 1737792000,
        "headline": "5 Best CEFs This Month For Nearly 10% Yield (January 2025)",
        "id": 132468888,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310121198/image_1310121198.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover high-yield closed-end funds for income investors with reasonable total returns. Click for our process of winnowing out the best CEFS this month.",
        "url": "https://finnhub.io/api/news?id=197c5be575be03a4b9586b3090506ccae90f12a685d42c55c0010fb160219701"
    },
    {
        "category": "company",
        "datetime": 1737735426,
        "headline": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
        "id": 132458795,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms",
        "url": "https://finnhub.io/api/news?id=fe221ce97276e6be8824900422af534ed79f47a1e23fbcfd197ae00334fb5db4"
    },
    {
        "category": "company",
        "datetime": 1737728285,
        "headline": "Amgen : North Carolina Ribbon Cutting Marks Important Milestone in Expansion to Meet Growing Demand for Amgen Medicines",
        "id": 132456067,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Amgen opened its newest cutting-edge drug substance facility in Holly Springs, North Carolina, with a ribbon cutting ceremony on January 24. The event took place less than two months after the biotech...",
        "url": "https://finnhub.io/api/news?id=39eb6f52bedffa4a870f7a833e0351dbac27f3cb9611f7f2359832ac0c324275"
    },
    {
        "category": "company",
        "datetime": 1737723964,
        "headline": "Amgen : Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products",
        "id": 132455818,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
        "url": "https://finnhub.io/api/news?id=59a3a651e5d9dcb1cbd37fe1675cb831f18443d3d09ee44e48b6035d0bc17dd7"
    },
    {
        "category": "company",
        "datetime": 1737710100,
        "headline": "DIVO: Hard To Create A Case For Income Investors, Who Seek Covered-Call Exposure",
        "id": 132454884,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1462286293/image_1462286293.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "We critique investing in DIVO due to lack of strategic rationale, compares to other covered call names JEPQ, FEPI, JEPI. Read an analysis of DIVO ETF here.",
        "url": "https://finnhub.io/api/news?id=186a1022c2bee483b36c08732a4ebd26de2ea98f52382e54fada8c71ff8d99e4"
    },
    {
        "category": "company",
        "datetime": 1737605869,
        "headline": "How To Invest $100,000 In The Ten Cheapest Dow Dividend 100 Stocks",
        "id": 132447070,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "SCHD is one of my favorite dividend funds. Check out the Top 20 holdings of SCHD and score them according to which, I believe, are the top 10 cheapest of the lot.",
        "url": "https://finnhub.io/api/news?id=7986981a49e059c451440c17aa615ffa1b9d38e9d37b2b0a7a28b252e7b8ab60"
    },
    {
        "category": "company",
        "datetime": 1737477780,
        "headline": "Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer",
        "id": 132460995,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer",
        "url": "https://finnhub.io/api/news?id=467d6d71ae3daccca52a8f3f0593d5af5a76f8f44bdca2e76ca5e6c7d3363912"
    },
    {
        "category": "company",
        "datetime": 1737442800,
        "headline": "Aristotle Value Equity Q4 2024 Commentary",
        "id": 132435477,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795167728/image_1795167728.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "For Q4 2024, Aristotle Capital\u00e2\u0080\u0099s Value Equity Composite posted a total return of -4.09% gross of fees. Read more here.",
        "url": "https://finnhub.io/api/news?id=ee2e7c48c55a0cc979a9b6b7b83a589a11ce1f320ff355afda806423aad9055e"
    },
    {
        "category": "company",
        "datetime": 1737378830,
        "headline": "Amgen: Likely To Be Rangebound (Rating Downgrade)",
        "id": 132431396,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630606163/image_1630606163.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives for biotech investors right now.",
        "url": "https://finnhub.io/api/news?id=a3eba74f8d6acab606d02765d5b37e6325e8da5e991ec514a58cd90554167ffd"
    },
    {
        "category": "company",
        "datetime": 1737368769,
        "headline": "AMGEN - FDA APPROVES LUMAKRAS IN COMBINATION WITH VECTIBIX FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
        "id": 132430644,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "THOUSAND OAKS - Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated...",
        "url": "https://finnhub.io/api/news?id=162bdbb03e4debf423de3c6f2c088516a11153aa13029ad575e1aad37ff972cf"
    },
    {
        "category": "company",
        "datetime": 1737305685,
        "headline": "Top 4 Immunology Stocks Poised For Growth In 2025",
        "id": 132426490,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover the latest trends and developments in the global immunology drugs market, along with four promising stocks to watch for potential investments.",
        "url": "https://finnhub.io/api/news?id=89d92fb4873b2558c4d0f5f75610a8a4ee6050f99c0d8d2410f07380589e1d07"
    },
    {
        "category": "company",
        "datetime": 1737113224,
        "headline": "Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC)",
        "id": 132415561,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Colorectal cancer is the third leading cause of cancer-related deaths in the United States.1 There is a critical need for more effective treatment options for patients with CRC, particularly for...",
        "url": "https://finnhub.io/api/news?id=5eebf267f3c6154fbffcebd120dc9075573fac8c0e856490e892d486654a5ee7"
    },
    {
        "category": "company",
        "datetime": 1737104525,
        "headline": "FDA APPROVES LUMAKRAS\u00ae (SOTORASIB) IN COMBINATION WITH VECTIBIX\u00ae (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER",
        "id": 132414916,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen today announced that the...",
        "url": "https://finnhub.io/api/news?id=162057ce328657abad1039a15325635ad46eaa6a9658b9788d9b457f1d6f442a"
    },
    {
        "category": "company",
        "datetime": 1737007436,
        "headline": "Tempering Positive Sentiment Of AI In Biotech",
        "id": 132404884,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163707266/image_2163707266.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=cd2ce10465b2022ad38901994024c990f366b0e2333aac6670be174216a19808"
    },
    {
        "category": "company",
        "datetime": 1736803805,
        "headline": "Amgen : 43rd Annual JP Morgan Healthcare Conference Presentation",
        "id": 132390662,
        "image": "",
        "related": "AMGN",
        "source": "Finnhub",
        "summary": "43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ROBERT A. BRADWAY, CHAIRMAN AND CHIEF EXECUTIVE OFFICER January 13, 2025 ...",
        "url": "https://finnhub.io/api/news?id=ea1c2813d0a1d609622f6184863989f98a17a7956d8af7bf73f2b1cc85fcd9f0"
    },
    {
        "category": "company",
        "datetime": 1736800616,
        "headline": "Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)",
        "id": 132390494,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen Inc. (NASDAQ:AMGN) 43rd Annual J.P.",
        "url": "https://finnhub.io/api/news?id=de747f34ffee3e71d97cddda0ddafce6d4b1cbebbcc4755e0251ba1e77760790"
    },
    {
        "category": "company",
        "datetime": 1736795665,
        "headline": "43rd Annual J.P. Morgan Healthcare Conference 2025",
        "id": 132390260,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The following slide deck was published by Amgen Inc.",
        "url": "https://finnhub.io/api/news?id=b420947326166dbf4d9541ee3048e7accd9998d6a310e1ed5cd157b72d5ae42d"
    },
    {
        "category": "company",
        "datetime": 1736791802,
        "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
        "id": 132390023,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
        "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    },
    {
        "category": "company",
        "datetime": 1736783580,
        "headline": "UnitedHealth, Caterpillar share gains lead Dow's 350-point climb",
        "id": 132407802,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "UnitedHealth, Caterpillar share gains lead Dow's 350-point climb",
        "url": "https://finnhub.io/api/news?id=a31a5666bf320ec51ebd89c83bca7ff5697050ab27c74dfe8c69cf229e8f5f8b"
    },
    {
        "category": "company",
        "datetime": 1736773140,
        "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
        "id": 132407804,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
        "url": "https://finnhub.io/api/news?id=acefd6c62b5e03c69f1a52f64769dcd68743f1fbdf4f7407acb14bb7b9c5ad1f"
    },
    {
        "category": "company",
        "datetime": 1736765823,
        "headline": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
        "id": 132407688,
        "image": "",
        "related": "AMGN",
        "source": "DowJones",
        "summary": "Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.",
        "url": "https://finnhub.io/api/news?id=37e2a928d2167d0048035cc98a3a4b5233aa2bc53c699711f8e55cded28f8379"
    },
    {
        "category": "company",
        "datetime": 1736747815,
        "headline": "SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate",
        "id": 132386392,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177260462/image_2177260462.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024. See why I rate SWTX stock a strong buy.",
        "url": "https://finnhub.io/api/news?id=8a4833b7c0dbcdf2a59ef3d7d12e8877cadca798aa4e02c468e92d343c93357c"
    },
    {
        "category": "company",
        "datetime": 1736570807,
        "headline": "Eli Lilly: Still Much Room To Ride The Weight-Loss Wave",
        "id": 132376826,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/147205781/image_147205781.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.",
        "url": "https://finnhub.io/api/news?id=c3f7280c3fbcdd9c9311cd40c8243dab4ff8ce623f2cde3ce54de3edcb55a822"
    },
    {
        "category": "company",
        "datetime": 1736424000,
        "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
        "id": 132349330,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
        "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d"
    },
    {
        "category": "company",
        "datetime": 1736421540,
        "headline": "Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug",
        "id": 132349846,
        "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.",
        "url": "https://finnhub.io/api/news?id=97dfe291c15cf5a857ca6a4e8b29154581b23d4de4791c5522b2f89782522693"
    },
    {
        "category": "company",
        "datetime": 1736370060,
        "headline": "AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE",
        "id": 132346054,
        "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
        "url": "https://finnhub.io/api/news?id=ac404adadb8fc814c26067160cf19d1aa87c3dc087836a4ef150000265b981cb"
    },
    {
        "category": "company",
        "datetime": 1736327815,
        "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
        "id": 132315626,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
        "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850"
    },
    {
        "category": "company",
        "datetime": 1736307720,
        "headline": "2024 Performance Review And Future Strategy",
        "id": 132312972,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about my 2024 performance here.",
        "url": "https://finnhub.io/api/news?id=3922811a6b45756cc6f38314d6b95f2b71818045c9380e9535a68114ed74797a"
    },
    {
        "category": "company",
        "datetime": 1736290221,
        "headline": "Amgen (AMGN) Advances While Market Declines: Some Information for Investors",
        "id": 132309560,
        "image": "https://s.yimg.com/ny/api/res/1.2/gZA5XMnsr1RRZw6lGNAcdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NDA-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.",
        "url": "https://finnhub.io/api/news?id=f3810436a2ce571827800dcf6645636f78ec42c1c9f4a07f1d5c37845dea633e"
    },
    {
        "category": "company",
        "datetime": 1736268000,
        "headline": "Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
        "id": 132324423,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
        "url": "https://finnhub.io/api/news?id=90f15c57730d67bc414d708aa3cbf7c4a3b7892e22a3851318b78c88fcff6fd6"
    },
    {
        "category": "company",
        "datetime": 1736258413,
        "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
        "id": 132301291,
        "image": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
        "url": "https://finnhub.io/api/news?id=5dff30ec16cb3e0ec268389dd35eb04203726857cd8d560a11dae6b194ddad57"
    },
    {
        "category": "company",
        "datetime": 1736249479,
        "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
        "id": 132302431,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
        "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    },
    {
        "category": "company",
        "datetime": 1736247480,
        "headline": "The Zacks Analyst Blog Highlights Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR",
        "id": 132299252,
        "image": "https://media.zenfs.com/en/zacks.com/7bc8bbeae2e0a87a69be234f543981cd",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR are part of the Zacks top Analyst Blog.",
        "url": "https://finnhub.io/api/news?id=8f23e9ddc0f246271a53d18f40e3764d84f7be88000a70bba4abee574f97afb8"
    },
    {
        "category": "company",
        "datetime": 1736204419,
        "headline": "Amgen (AMGN) Stock Sinks As Market Gains: Here's Why",
        "id": 132294847,
        "image": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.",
        "url": "https://finnhub.io/api/news?id=6385fe87a20f56dc977c5bd8c352a443c989e60fdac808ba4a344c91901a26ff"
    },
    {
        "category": "company",
        "datetime": 1736197920,
        "headline": "Top Analyst Reports for Microsoft, Exxon Mobil & Amgen",
        "id": 132292806,
        "image": "https://media.zenfs.com/en/zacks.com/d325e443265f81b37d14d0c390b4cefa",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Amgen Inc. (AMGN), as well as two micro-cap stocks PrimeEnergy Resources Corporation (PNRG) and FONAR Corporation (FONR).",
        "url": "https://finnhub.io/api/news?id=25330f3372284582a64b0014220c95fa9ad2bccec8a19851f3453b2494a84ef3"
    },
    {
        "category": "company",
        "datetime": 1736183416,
        "headline": "Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?",
        "id": 132291660,
        "image": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
        "url": "https://finnhub.io/api/news?id=ccb3ad2980d8a3d816fbabe28c93266d1edaddc91fb275ddcdff491056d83447"
    },
    {
        "category": "company",
        "datetime": 1736167917,
        "headline": "Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year",
        "id": 132291661,
        "image": "https://media.zenfs.com/en/simply_wall_st__316/7137ef364be97d9882cfa4ec57169a99",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th of...",
        "url": "https://finnhub.io/api/news?id=58b001d2fd13cce780b0bf67ac0837402e3b5f0f6ed6a25e88a778efa4694826"
    },
    {
        "category": "company",
        "datetime": 1736167424,
        "headline": "Amgen\u2019s Imdylltra wins conditional MHRA licence for lung cancer",
        "id": 132286679,
        "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/01/shutterstock_1953872293.jpg",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen\u2019s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.",
        "url": "https://finnhub.io/api/news?id=79dbaf209746b03133960cc3b88fdf3bba7179b7b3c7f33ce6e48fe48583ae43"
    },
    {
        "category": "company",
        "datetime": 1736148600,
        "headline": "Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)",
        "id": 132285461,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412046220/image_1412046220.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold to buy.",
        "url": "https://finnhub.io/api/news?id=b410dbfe3eb2d686d3212cfa9a6a95ba6bef0f35e9f8733220a6c9734f3064de"
    },
    {
        "category": "company",
        "datetime": 1736144723,
        "headline": "Amgen: Growth Potential Met By High Debt Levels",
        "id": 132284910,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324349/image_1418324349.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Explore more details here.",
        "url": "https://finnhub.io/api/news?id=e7f898733e64a356cc014206807e225b9e1c522dfe9973dfe3cae5913910c56f"
    },
    {
        "category": "company",
        "datetime": 1736104716,
        "headline": "Amgen: Blockbusters, Emerging Therapies, And Investment Potential",
        "id": 132281384,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411285056/image_1411285056.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy for long-term investors.",
        "url": "https://finnhub.io/api/news?id=b2cb4d553970a45772f66a5f1f2827cbc5f1c1390dfc62e2ad70af2f904bc943"
    },
    {
        "category": "company",
        "datetime": 1736086947,
        "headline": "Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold",
        "id": 132279730,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.",
        "url": "https://finnhub.io/api/news?id=d6e2bada4590e6cb2a8a0f476dcec9117273e7206fb178f2a5f2430389dceffb"
    },
    {
        "category": "company",
        "datetime": 1735991280,
        "headline": "Prediction: These 3 Healthcare Stocks Will Soar in 2025",
        "id": 132268525,
        "image": "https://g.foolcdn.com/editorial/images/802692/stock-chart-rocket.jpg",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Here's why they chose Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Summit Therapeutics (NASDAQ: SMMT).  David Jagielski (Amgen): Shares of Amgen started crashing in late November following the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide.",
        "url": "https://finnhub.io/api/news?id=1c8954e87e40b08cccb040ec3b670cc0f62d88f6b2426631d3df84521d6aaeb5"
    },
    {
        "category": "company",
        "datetime": 1735922340,
        "headline": "Amgen Inc. stock rises Friday, still underperforms market",
        "id": 132324424,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock rises Friday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=9156e25cf407f4234de6caeb436b10ae49c60256f39752b1d30b20b94c5827f6"
    },
    {
        "category": "company",
        "datetime": 1735911000,
        "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
        "id": 132253611,
        "image": "https://g.foolcdn.com/editorial/images/802493/23_08_01-a-hand-writing-top-3-on-a-clear-screen-_mf-dload.jpg",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The Dow Jones Industrial Average\u00a0contains 30 handpicked companies that are, or at least once were, leaders in their respective industries.  Right now the three highest yielding Dow stocks are Verizon Communications\u00a0(NYSE: VZ), Chevron (NYSE: CVX), and Amgen (NASDAQ: AMGN).  Verizon is one of the largest telecom companies in the United States.",
        "url": "https://finnhub.io/api/news?id=f3fc40ff98255e7afc60de7e6e61d15b57ec9d5540dc940c375ee57ce06c4376"
    },
    {
        "category": "company",
        "datetime": 1735835940,
        "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors",
        "id": 132324425,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=e07a3bfbadde23d425c2951bd7abea3c9468f151da2f4a5c9f1903fc4197478b"
    },
    {
        "category": "company",
        "datetime": 1735820503,
        "headline": "January Dow Dogs: 1 'Safer' Buy, And 5 With Promise",
        "id": 132240262,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/478792228/image_478792228.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Get insights on top Dow Dogs like Verizon and Merck, with potential net gains forecasted by analysts. Click for the January picks.",
        "url": "https://finnhub.io/api/news?id=a2bfec130e38310a0339d2950fb14a024997156e837c950640f2806e609acfa0"
    },
    {
        "category": "company",
        "datetime": 1735795200,
        "headline": "Not A Year For The 2024 Dogs Of The Dow",
        "id": 132237169,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1854380206/image_1854380206.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "With the close of trading for 2024 occurring on Tuesday, it is time to look at the performance of those Dogs of the Dow. Read more here.",
        "url": "https://finnhub.io/api/news?id=28c6a445e8e9a1d5a082ef979aa21a6b9db0edad6601803c67794cbbb92d3e75"
    },
    {
        "category": "company",
        "datetime": 1735732980,
        "headline": "The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024",
        "id": 132226604,
        "image": "",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.",
        "url": "https://finnhub.io/api/news?id=cf7f3a696e0e56a3cd01b865ec5627e3b730f312cc93b2897bf9e4b8f3312dab"
    },
    {
        "category": "company",
        "datetime": 1735681738,
        "headline": "GLP-1 questions emerge for 2025",
        "id": 132221988,
        "image": "https://s.yimg.com/ny/api/res/1.2/o.xKVkL_2cKm_990lun34w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2023-12/2d578f90-9d7d-11ee-bd6d-e9421ec244af",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.",
        "url": "https://finnhub.io/api/news?id=10d16fd7419a29a826adae343cff42b8cce630ca6029cd6b54f4057e9d8f8745"
    },
    {
        "category": "company",
        "datetime": 1735649392,
        "headline": "Akero Therapeutics: Where This Potential MASH Play Stands Currently",
        "id": 132216255,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of $2 billion. Click for my AKRO update.",
        "url": "https://finnhub.io/api/news?id=59f1490761432441566bcb1c76e1b8ca8e84060130f68c53918f19c2e06d32c5"
    },
    {
        "category": "company",
        "datetime": 1735603260,
        "headline": "This Biotech Is One of the S&P 500\u2019s Worst Performers. It Looks Too Cheap.",
        "id": 132324426,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "This Biotech Is One of the S&P 500\u2019s Worst Performers. It Looks Too Cheap.",
        "url": "https://finnhub.io/api/news?id=372459c0450a0a8c44bad940edc33a0deb4f95ee859cf2bb4a3316f84f8972be"
    },
    {
        "category": "company",
        "datetime": 1735599619,
        "headline": "Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights",
        "id": 132208497,
        "image": "",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.",
        "url": "https://finnhub.io/api/news?id=91617169e09e86e84d8201fe375ceacdc1c0d035ec0dfc5a09379882c261aad9"
    },
    {
        "category": "company",
        "datetime": 1735594573,
        "headline": "Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?",
        "id": 132206494,
        "image": "https://s.yimg.com/ny/api/res/1.2/Umivb7Omy8VqKH22zTmY9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower [\u2026]",
        "url": "https://finnhub.io/api/news?id=011c861318c049d7049fdbf638c840a4e4f1f47f98e00b8b5931ac5db710de59"
    },
    {
        "category": "company",
        "datetime": 1735585359,
        "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
        "id": 132207437,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459000811/image_459000811.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
        "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a"
    },
    {
        "category": "company",
        "datetime": 1735310410,
        "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
        "id": 132178826,
        "image": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "url": "https://finnhub.io/api/news?id=e5250ed02a0bf37e5e815c5622b1d915f1a7658f7e5eb1f3edcf011ee40ab988"
    },
    {
        "category": "company",
        "datetime": 1735282800,
        "headline": "3 Healthcare Stocks to Buy for a 2025 Rebound",
        "id": 132173130,
        "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Healthcare stocks have gotten crushed in 2024, and next year doesn\u2019t look much better.  Recent developments, including a bipartisan bill calling for insurers to separate from their pharmacy benefit management units, or PBMs, has caused pain, but the sector has been unloved for most of the last 11 months and change.",
        "url": "https://finnhub.io/api/news?id=3708c7a3927019e64f3137eb67d5009f9f5bed7f8b42aece67fae6163ec3675f"
    },
    {
        "category": "company",
        "datetime": 1735205436,
        "headline": "PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.",
        "id": 132164310,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/832255342/image_832255342.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.",
        "url": "https://finnhub.io/api/news?id=d9924bfb15be4a412c5d30ffc3c153fb65db609d6f0526759c3ece67141e5e6e"
    },
    {
        "category": "company",
        "datetime": 1735205400,
        "headline": "2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone",
        "id": 132164311,
        "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.",
        "url": "https://finnhub.io/api/news?id=926999938b0fe33f3c1fc7c0ca1e5db52929e7393e238aee36c364dbfcb94eb1"
    },
    {
        "category": "company",
        "datetime": 1735069500,
        "headline": "What's next for GLP-1 weight-loss drugs in 2025?",
        "id": 132136182,
        "image": "",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments. Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025. Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year. To watch more expert insights and analysis on the latest market action, check out more Market Domination\u00a0here. This post was written by Angel Smith",
        "url": "https://finnhub.io/api/news?id=1f029c1f3a96f8489dbc131709c904839c81db9b41de6f89c972de54abae3e79"
    },
    {
        "category": "company",
        "datetime": 1735060800,
        "headline": "3 biggest catalysts expected for healthcare in 2025",
        "id": 132133934,
        "image": "https://s.yimg.com/ny/api/res/1.2/beEG94ULzRzpQ6PW9JqZAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/664ed980-c215-11ef-af3f-16c0199a30a2",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts\u00a0here. This post was written by Luke Carberry Mogan.",
        "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af"
    },
    {
        "category": "company",
        "datetime": 1735058340,
        "headline": "Amgen Inc. stock rises Tuesday, still underperforms market",
        "id": 132147761,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock rises Tuesday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=6a26a7cca558d43bc71c37c4f164d996c577b5735580da9b7dd9668a3d5beece"
    },
    {
        "category": "company",
        "datetime": 1734994218,
        "headline": "Here's Why Amgen (AMGN) Gained But Lagged the Market Today",
        "id": 132132719,
        "image": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.",
        "url": "https://finnhub.io/api/news?id=2ba54ad17eeb15ee76f9d1db1b40e0943a7d978a46ce71b25b12f084369eca87"
    },
    {
        "category": "company",
        "datetime": 1734971940,
        "headline": "Amgen Inc. stock rises Monday, still underperforms market",
        "id": 132147762,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock rises Monday, still underperforms market",
        "url": "https://finnhub.io/api/news?id=70ccdcc714a881d3edf67d3de3ce157b8fd95618bac906b1e426b3fd94458533"
    },
    {
        "category": "company",
        "datetime": 1734968760,
        "headline": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
        "id": 132145561,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
        "url": "https://finnhub.io/api/news?id=43d97b071a263f9bb49a3c83572213b633af95cb84fdba908a8325f163d7f5d4"
    },
    {
        "category": "company",
        "datetime": 1734962411,
        "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
        "id": 132121437,
        "image": "https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
        "url": "https://finnhub.io/api/news?id=818702966625ee5e4ffff5088e320d6fea335ceb250eb045bf184d7bc8ca4b08"
    },
    {
        "category": "company",
        "datetime": 1734961680,
        "headline": "Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?",
        "id": 132121438,
        "image": "https://media.zenfs.com/en/zacks.com/c044de49a07dc50d6afbd14846fc644c",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
        "url": "https://finnhub.io/api/news?id=9451830a5429e23ec275207e5ae78d2edd9d5184d0f23ff9c9e99be5f8e507b1"
    },
    {
        "category": "company",
        "datetime": 1734959760,
        "headline": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
        "id": 132121202,
        "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
        "url": "https://finnhub.io/api/news?id=31cd3e22b1483200418a001b32ab70a52840e9a671ba2882befbfdaa994d9946"
    },
    {
        "category": "company",
        "datetime": 1734956524,
        "headline": "Hot Obesity Drug Market Will Keep Investors Gripped Next Year",
        "id": 132117993,
        "image": "https://media.zenfs.com/en/bloomberg_markets_842/d6d8e08ee049366cd32f1c0ad2b087b7",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S\u2019s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma\u2019s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York\u2019s Congestion Pricing Plan Still Faces Legal HurdlesNew York City\u2019s Historic Preservation Movement Is Having a Midlife CrisisNovo sh",
        "url": "https://finnhub.io/api/news?id=8627274ffe00c98c4f130143de0907fd1d833a955e597066c397b45dfb1c4edc"
    },
    {
        "category": "company",
        "datetime": 1734946320,
        "headline": "2 Excellent Dividend Stocks to Buy on the Dip",
        "id": 132117199,
        "image": "https://g.foolcdn.com/editorial/images/801657/pharmacist-talking-to-patient.jpg",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common.  Both also recently saw their shares fall significantly in one day, following unimpressive clinical data for otherwise promising candidates.  The company's $8.7 billion buyout of Cerevel Therapeutics now looks like a waste of money after the leading asset it got from that transaction, emraclidine, failed a pair of phase 2 studies.",
        "url": "https://finnhub.io/api/news?id=dd89758c20e726a1dcb8a744f07157cad74c75fb20707e21f3733b108b54b176"
    },
    {
        "category": "company",
        "datetime": 1734856611,
        "headline": "BME: 8.4% Yield From An Undervalued Sector",
        "id": 132109258,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2096299665/image_2096299665.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "An analysis of BlackRock Health Sciences Trust, previously rated as a hold, now considered a Buy due to sector overselling and potential growth.",
        "url": "https://finnhub.io/api/news?id=b82751925b2c258cbe9aa5d0585ebf4c94a372a0f8ac7804f6a79d723d8bb24e"
    },
    {
        "category": "company",
        "datetime": 1734784243,
        "headline": "Novo obesity data positive for Eli Lilly and Amgen, says UBS",
        "id": 132095943,
        "image": "https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "UBS analyst Trung Huynh says Novo Nordisk\u2019s (NVO) CagriSema Phase 3 topline obesity data \u201cunderwhelmed,\u201d a positive read-through to Eli Lilly (LLY) and Amgen (AMGN). CagriSema achieved an average weight loss of 20.4%, below Novo\u2019s prior guidance of 25% and inferior to Lilly\u2019s tirzepatide at a similar timepoint, the analyst tells investors in a research note. UBS views the CagriSema\u2019s obesity readout a positive read-through to Lilly, \u201cvalidating again tirzepatide\u2019s best-in-class profile.\u201d It also",
        "url": "https://finnhub.io/api/news?id=7daf6f13d49aa39a0fb0bd1707c87219e5838015a83bb866ad16198c58c11208"
    },
    {
        "category": "company",
        "datetime": 1734724080,
        "headline": "Novo Nordisk Shares Plunge After New Obesity Shot Disappoints",
        "id": 132080045,
        "image": "",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company\u2019s next blockbuster weight loss drug.",
        "url": "https://finnhub.io/api/news?id=9ee3a9cdcf66fd04e663d7ee60b6f67cbc9e6ae9267b93420a2dc44abe95cd38"
    },
    {
        "category": "company",
        "datetime": 1734719769,
        "headline": "Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.",
        "id": 132079421,
        "image": "https://media.zenfs.com/en/ibd.com/46c18cf5ac864a5f2306cbef485a793d",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.",
        "url": "https://finnhub.io/api/news?id=dc041da50e6e44284cc65bce2bc914dfd8fabf08d2b05a05c3ef84355fb1c036"
    },
    {
        "category": "company",
        "datetime": 1734701580,
        "headline": "Dow up 650 points on gains for shares of Goldman Sachs, NVIDIA Corp.",
        "id": 132145689,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Dow up 650 points on gains for shares of Goldman Sachs, NVIDIA Corp.",
        "url": "https://finnhub.io/api/news?id=2106487ed0c0f7df464e8d4885aead3b2bd2cec5740072cb5d1e9e7b9b9f0a7d"
    },
    {
        "category": "company",
        "datetime": 1734696189,
        "headline": "Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.",
        "id": 132071759,
        "image": "https://media.zenfs.com/en/ibd.com/46c18cf5ac864a5f2306cbef485a793d",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped",
        "url": "https://finnhub.io/api/news?id=936f47d99c8a4549bb27b69c5bd0f2d3c76323b59add70e122ba8e9ecbe1c59f"
    },
    {
        "category": "company",
        "datetime": 1734690600,
        "headline": "Goldman Sachs, Salesforce share gains lead Dow's 300-point jump",
        "id": 132145532,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Goldman Sachs, Salesforce share gains lead Dow's 300-point jump",
        "url": "https://finnhub.io/api/news?id=c9118a2b8f5b5b78370644b27242912d2fd3c472f3ea265438a46d661d11fb1f"
    },
    {
        "category": "company",
        "datetime": 1734607238,
        "headline": "Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In?",
        "id": 132051245,
        "image": "https://s.yimg.com/ny/api/res/1.2/Umivb7Omy8VqKH22zTmY9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
        "related": "AMGN",
        "source": "Yahoo",
        "summary": "We recently compiled a list of the 10 Dogs of the Dow Dividend Stocks to Invest in. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields, shaping their strategies around acquiring such investments. A [\u2026]",
        "url": "https://finnhub.io/api/news?id=1949717cf60385f48a0ede40bb737fbebddab48845892daee28afc4f93e274e9"
    },
    {
        "category": "company",
        "datetime": 1734539940,
        "headline": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
        "id": 132066871,
        "image": "",
        "related": "AMGN",
        "source": "MarketWatch",
        "summary": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
        "url": "https://finnhub.io/api/news?id=edbff0a24f18c65b5f23e12c22ee027fe8c2f8064a3837532a4cfa8f12ae7b44"
    },
    {
        "category": "company",
        "datetime": 1734519362,
        "headline": "Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation",
        "id": 132039547,
        "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1464160868/image_1464160868.jpg?io=getty-c-w1536",
        "related": "AMGN",
        "source": "SeekingAlpha",
        "summary": "Viridian's veligrotug shows promising results in treating TED patients, setting the stage for future growth in the biopharmaceutical company. Read more here.",
        "url": "https://finnhub.io/api/news?id=53a707effab74db195b8f76c7bd18a3bdf2d4ef5cf930ec983759d9bc87a71fc"
    }
]